| (210) | Number of the EPO application | 17703376 |
| (220) | Filing date of the EPO application | 2017.02.02 |
| (80) | EPO patent specification publication (B) | EPB nr. 51/2021, 2021.12.22 |
| (110) | EPO patent number | 3411402 |
| (11) | Number of the document | MD 3411402 T2 |
| (21) | Number of the application | e 2018 1178 |
| (71) | Name(s) of applicant(s), code of the country | Amgen Research (Munich) GmbH, DE;
Amgen Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | RAUM Tobias, DE;
MUENZ Markus, DE;
BROZY Johannes, DE;
KUFER Peter, DE;
HOFFMANN Patrick, DE;
FRIEDRICH Matthias, DE;
RATTEL Benno, DE;
BOGNER Pamela, DE;
WOLF Andreas, DE;
POMPE Cornelius, DE; |
| (73) | Name(s) of owner(s), code of the country | AMGEN Research (Munich) GmbH, DE;
AMGEN Inc., US; |
| (54) | Title of the invention | BCMA and CD3 bispecific T cell engaging antibody constructs |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | C07K 16/28 (2006.01.01) |
| (19) | Country | DE |
| (41) | Date of publication of the application | 2019.01.31 |
| (49) | Date of publication of the translation of the validated European patent specification | 2022.05.31 |
| (30) | Priority | 201662290831 P, 2016.02.03, US |
| (74) | Patent attorney | (Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova |
| (86) | International application | PCT/EP2017/052202, 2017.02.02 |
| (87) | International publication | WO 2017/134134, 2017.08.10 |